INDEPENDENT ORIGINS OF CYSTIC-FIBROSIS MUTATIONS R334W, R347P, R1162X, AND 3849+10KBC-]T PROVIDE EVIDENCE OF MUTATION RECURRENCE IN THE CFTR GENE

被引:0
|
作者
MORRAL, N
LLEVADOT, R
CASALS, T
GASPARINI, P
MACEK, M
DORK, T
ESTIVILL, X
机构
[1] HOSP DURAN I REYNALS,INST RECERCA ONCOL,DEPT MOLEC GENET,E-08907 LHOSPITALET LLOBR,SPAIN
[2] IRCCS,OSPED CASA SOLLIEVO SOFFEREZA,SERV GENET MED,FOGGIA,ITALY
[3] JOHNS HOPKINS MED INST,CTR MED GENET,BALTIMORE,MD 21205
[4] CHARLES UNIV,FAC MED 1,PRAGUE,CZECH REPUBLIC
[5] HANNOVER MED SCH,ZENTRUM BIOCHEM,HANNOVER,GERMANY
关键词
D O I
暂无
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Microsatellite analysis of chromosomes carrying particular cystic fibrosis mutations has shown different haplotypes in four cases: R334W, R347P, R1162X, and 3849+10kbC-->T. To investigate the possibility of recurrence of these mutations, analysis of intra- and extragenic markers flanking these mutations has been performed. Recurrence is the most plausible explanation, as it becomes necessary to postulate either double recombinations or single recombinations in conjunction with slippage at one or more microsatellite loci, to explain the combination of mutations and microsatellites if the mutations arose only once. Also in support of recurrence, mutations R334W, R347P, R1162X, and 3849+10kbC-->T invohre CpG dinucleotides, which are known to have an increased mutation rate. Although only 15.7% of point mutations in the coding sequence of CFTR have occurred at CpG dinucleotides, approximately half of these CpG sites have mutated at least once. Specific nucleotide positions of the coding region of CFTR, distinct from CpG sequences, also seem to have a higher mutation rate, and so it is possible that the mutations observed are recurrent. G-->A transitions are the most common change found in those positions involved in more than one mutational event in CFTR.
引用
收藏
页码:890 / 898
页数:9
相关论文
共 5 条
  • [1] Gene Therapy to Rescue the Premature Stop Cystic Fibrosis Mutations R1162X and W1282X
    Boinot, Clement
    Sabirzhanova, Inna
    Guggino, William
    Cebotaru, Liudmila
    [J]. MOLECULAR THERAPY, 2017, 25 (05) : 259 - 260
  • [2] 9 CYSTIC-FIBROSIS PATIENTS HOMOZYGOUS FOR THE CFTR NONSENSE MUTATION R1162X HAVE MILD OR MODERATE LUNG-DISEASE
    GASPARINI, P
    BORGO, G
    MASTELLA, G
    BONIZZATO, A
    DOGNINI, M
    PIGNATTI, PF
    [J]. JOURNAL OF MEDICAL GENETICS, 1992, 29 (08) : 558 - 562
  • [3] NONSENSE MUTATION R1162X OF THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE DOES NOT REDUCE MESSENGER-RNA EXPRESSION IN NASAL EPITHELIAL TISSUE
    ROLFINI, R
    CABRINI, G
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06): : 2683 - 2687
  • [4] IDENTIFICATION OF 6 MUTATIONS (R31L, 441DELA, 681DELC, 1461INS4, W1089R, E1104X) IN THE CYSTIC-FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE
    ZIELENSKI, J
    MARKIEWICZ, D
    CHEN, HS
    SCHAPPERT, K
    SELLER, A
    DURIE, P
    COREY, M
    TSUI, LC
    [J]. HUMAN MUTATION, 1995, 5 (01) : 43 - 47
  • [5] Outcome of intracytoplasmic sperm injection for a couple in which the man is carrier of CFTR p.[R74W;V201M;D1270N] and p.P841R mutations and his spouse a heterozygous carrier of p.F508del mutation of the cystic fibrosis transmembrane conductance regulator gene
    Brugnon, Florence
    Bilan, Frederic
    Heraud, Marie-Christine
    Grizard, Genevieve
    Janny, Laurent
    Creveaux, Isabelle
    [J]. FERTILITY AND STERILITY, 2008, 90 (05) : 2004.e23 - 2004.e26